Ambulatorium Sp. z o.o.

Running trials

• Recruiting

  A Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight

  2025-524616-11-00· Phase 3· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· Phase 3· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Source

• Not yet recruiting

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

  2025-522471-28-00· Phase 3· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  NCT07282600· Phase 3· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· Phase 3· Source

• Recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

  NCT06878404· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

  NCT06807424· Phase 3· Source

• Recruiting

  A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

  NCT06454188· Phase 4· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2)

  2022-500700-22-00· Phase 3· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Psoriatic arthritis3 recruiting
• Type 2 diabetes3 recruiting
• Psoriasis2 recruiting
• Ankylosing spondylitis1 recruiting
• Chronic kidney disease1 recruiting
• Stroke1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Source

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Source

• Completed

  A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis

  2024-510826-16-00· Phase 3· Source

• Completed

  A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease

  2024-512986-15-00· Phase 2· Source

• Completed

  A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis

  2024-512417-41-00· Phase 3· Source

• Completed

  Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS)

  2023-503915-14-00· Phase 2· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Source

• Completed

  A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis

  2022-501425-20-00· Phase 2· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Phase 3· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Source